Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8901 results

  1. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

  2. Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]

    Topic prioritisation

  3. Galcanezumab for migraine [TSID10663]

    Topic prioritisation

  4. Thermal Probe Ablation for abdominal wall endometriosis

    Topic prioritisation

  5. Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]

    Topic prioritisation

  6. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

  7. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

  8. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

  9. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [TSID12287]

    Topic prioritisation

  10. Transverse Tibial Transport

    Topic prioritisation

  11. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 13 February 2026.

  12. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

  13. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC